Auteurs
Analysis
Allemagne
Racine
Analysis
Allemagne
Exploration
Accueil
Racine
Racine

Serveur d'exploration sur les relations entre la France et l'Australie - Analysis (Allemagne)

Index « Auteurs » - entrée « Mayur M. Amonkar »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Mayumi Ueta < Mayur M. Amonkar < Mayuri Chandra  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 2.
Ident.Authors (with country if any)Title
000C76 (2015) Dirk Schadendorf [Allemagne] ; Mayur M. Amonkar [États-Unis] ; Daniil Stroyakovskiy [Russie] ; Evgeny Levchenko [Russie] ; Helen Gogas [Grèce] ; Filippo De Braud [Italie] ; Jean-Jacques Grob [France] ; Igor Bondarenko [Ukraine] ; Claus Garbe [Allemagne] ; Celeste Lebbe [France] ; James Larkin [Royaume-Uni] ; Vanna Chiarion-Sileni [Italie] ; Michael Millward [Australie] ; Ana Arance [Espagne] ; Mario Mandalà [Italie] ; Keith T. Flaherty [États-Unis] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Caroline Robert [France] ; Michelle Casey [États-Unis] ; Douglas J. Demarini [États-Unis] ; Jhangir G. Irani [États-Unis] ; Gursel Aktan [États-Unis] ; Georgina V. Long [Australie]Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
000D76 (2015) Jean Jacques Grob [France] ; Mayur M. Amonkar [États-Unis] ; Boguslawa Karaszewska [Pologne] ; Jacob Schachter [Israël] ; Reinhard Dummer [Suisse] ; Andrzej Mackiewicz [Pologne] ; Daniil Stroyakovskiy [Russie] ; Kamil Drucis [Pologne] ; Florent Grange [France] ; Vanna Chiarion-Sileni [Italie] ; Piotr Rutkowski [Pologne] ; Mikhail Lichinitser [Russie] ; Evgeny Levchenko [Russie] ; Pascal Wolter [Belgique] ; Axel Hauschild [Allemagne] ; Georgina V. Long [Australie] ; Paul Nathan [Royaume-Uni] ; Antoni Ribas [États-Unis] ; Keith Flaherty [États-Unis] ; Peng Sun [États-Unis] ; Jeffrey J. Legos [États-Unis] ; Diane Opatt Mcdowell [États-Unis] ; Bijoyesh Mookerjee [États-Unis] ; Dirk Schadendorf [Allemagne] ; Caroline Robert [France]Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

List of associated KwdEn.i

Nombre de
documents		Descripteur
2Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
2Humans
2Imidazoles (administration & dosage)
2Imidazoles (adverse effects)
2Melanoma (drug therapy)
2Melanoma (genetics)
2Oximes (administration & dosage)
2Oximes (adverse effects)
2Proto-Oncogene Proteins B-raf (genetics)
2Pyridones (administration & dosage)
2Pyridones (adverse effects)
2Pyrimidinones (administration & dosage)
2Pyrimidinones (adverse effects)
2Quality of Life
2Skin Neoplasms (drug therapy)
2Skin Neoplasms (genetics)
2Skin Neoplasms (pathology)
1Administration, Oral
1Amino Acid Substitution
1Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
1Antineoplastic Combined Chemotherapy Protocols (adverse effects)
1Biomarkers, Tumor (genetics)
1DNA Mutational Analysis
1Disease Progression
1Disease-Free Survival
1Drug Administration Schedule
1Genetic Predisposition to Disease
1Health Status
1Imidazoles (therapeutic use)
1Indoles (administration & dosage)
1Indoles (adverse effects)
1Indoles (therapeutic use)
1Intention to Treat Analysis
1MAP Kinase Kinase Kinases (antagonists & inhibitors)
1MAP Kinase Kinase Kinases (metabolism)
1Melanoma (mortality)
1Melanoma (pathology)
1Melanoma (secondary)
1Mutation
1Neoplasm Metastasis
1Oximes (therapeutic use)
1Pain Measurement
1Phenotype
1Prospective Studies
1Protein Kinase Inhibitors (administration & dosage)
1Protein Kinase Inhibitors (adverse effects)
1Protein Kinase Inhibitors (therapeutic use)
1Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
1Pyridones (therapeutic use)
1Pyrimidinones (therapeutic use)
1Risk Factors
1Skin Neoplasms (mortality)
1Sulfonamides (administration & dosage)
1Sulfonamides (adverse effects)
1Sulfonamides (therapeutic use)
1Surveys and Questionnaires
1Time Factors
1Treatment Outcome
1Valine (genetics)

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Allemagne/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i -k "Mayur M. Amonkar" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Allemagne/Analysis/Author.i  \
                -Sk "Mayur M. Amonkar" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Allemagne/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Allemagne
   |étape=   Analysis
   |type=    indexItem
   |index=    Author.i
   |clé=    Mayur M. Amonkar
}}
Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024